spot_img

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002

Figure 1. Structure of complex of SARS-CoV-2 Omicron variant spike protein RBD bound to ACE2. A. Overall structure and conformation of ACE2-RBD complex. B. RBD-ACE2 interaction interface. C. The interaction interface of RBD dimer.

Joint research results from Biologics of Jemincare and Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effective against the Omicron variant of SARS-CoV-2.

A team of scientists led by Dr. Su-Jun Deng from biologics of Jemincare R&D Center, and another team of scientists from SIMM of CAS, led by Professor H. Eric Xu and Dr. Wanchao Yin, not only confirmed the binding and pseudovirus neutralization activity of JMB2002 against Omicron variant but also solved the structures of Omicron spike protein in complex with ACE2 and JMB2002 respectively (Figure 1 and Figure 2). Joint research efforts revealed the mechanisms of increased infectivity and immune escape of the Omicron variant at the molecular level and demonstrated the unique binding mechanism of JMB2002 differing from all reported NAbs. Detailed findings of novel features of the Omicron variant and JMB2002 have been published on the bioRxiv preprint website (Reference 1).

The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed a potent Omicron pseudovirus neutralization function (Figure 2A, 2B). It is encouraging considering that most approved and clinical-stage SARS-CoV-2 neutralizing antibody drugs have lost their neutralization activity or have shown significantly reduced neutralizing potency due to multiple mutations of the spike protein in the Omicron variant.

One reason for the enhanced infectivity of the Omicron variant is that its spike protein RBD (Receptor Binding Domain) has a higher binding ability to the SARS-CoV-2 receptor ACE2 than that of wild type. There are immediate needs for developing specific therapeutic antibodies targeting the Omicron variant. Scientists from Jemincare found that the binding affinity of JMB2002 Fab to the spike protein of the Omicron variant is 4-fold higher than that of WT (Figure 2A). More importantly, professor H. Eric Xu’s group has solved the structure of the complex of Omicron spike trimer bound to JMB2002 (Figure 2C), the structure shows JMB2002 binds to the back of RBD, a unique binding epitope with novel conformation (Figure 2D). It suggests that JMB2002 is a new class of SARS-CoV-2 neutralizing antibody with a binding mechanism different from all reported NAbs, classifying as class V NAb. The results from the pseudovirus neutralization assay indicate that JMB2002 is a broad-spectrum neutralizing antibody targeting all WHO VOC except the Delta variant (Reference 1).

JMB2002 has finished phase I clinical trial in China

In June 2021, JMB2002 has finished Phase I clinical trial in healthy donors in China with excellent safety and desirable PK properties. In March 2021, JMB2002 has been approved for a clinical trial in US (IND 154745). At present, Jemincare produced enough JMB2002 drug substance for further clinical investigation at 2000L bioreactor scale.

SOURCE: Jemincare




I want to grow my online platform to create awareness about ethical consumerism, environmentalism, and the plant-based lifestyle. My main mission is to share information that empowers people to make better choices and create a VEG NEW WORLD :)


Your support is vital and is helping me share the collected information with thousands of readers and viewers. I try to deliver exclusive stories and relevant content in a challenging commercial environment. Your contribution helps me to cover the costs that my service requires. Please consider contributing (no matter how small) to keep the information flowing so you can remain informed and have life changing interviews and stories to share.

spot_img

Subscribe

Related articles

Remy Robotics exits stealth mode with launch of third autonomous robotic kitchen

  Pioneer in robot-enabled delivery-only restaurants expands its reach and...

GUUD Modern Muesli Launches Functional Cereal Line

New ‘Fuel’ Products Take Breakfast to the Next Level GUUD,...

Yoga guru offers free guided meditation for World Meditation Day

  Available online for participants across the globe, or in-person...

Fleur & Bee Releases Beginner-Friendly Retinol Moisturizer

Clean skincare brand Fleur & Bee officially debuts its...
spot_img
Betty Tűndikhttps://vegnew.world
Hi everyone! Nice to e-meet you! Here are a few things you should know about me. I am a conscientious, open-minded, adaptable to new experiences, and ambitious Business Development Manager with a Bachelor's Degree in Economics - Banking, Finance, and Accountancy. Through my studies, I've also obtained many naturopathic and nutrition degrees as well. Part-time jobs have added marketing, network marketing, event management, and store management skills to my experience throughout my career. Throughout my career, I have also been a Hotel Manager and owned a Bar/Restaurant & Internet Cafe. My online marketing and social media interactivity experience was gained when I and my husband started a business with an online/organic webshop & healthy lifestyle consultancy. I've improved my English at Cambridge Academy of English - 2003, in Cambridge. I live a conscious lifestyle, and try to protect the ecosystem. Animal lover and capable of helping others without judgment or negative reactions, this is thanked my knowledge in holistic therapies and the naturopathy courses I've followed. I cannot leave for my spiritual growth and the continuous development in alternative and holistic therapies, so I'm learning at Kyron School of New Consciousness, receiving a Bio Energo-therapist diploma. Thanks to all my experiences I've decided to venture into publishing and writing, while also continuing to learn many new things daily. I hope you enjoy reading my hand-picked news and check back for my weekly articles.

LEAVE A REPLY

Please enter your comment!
Please enter your name here